Lisata Therapeutics Inc

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for three months ended March 31, 2024, on Thursday, May 9, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults. LSTA1 recently received Rare Pediatric Disease Designation for osteosarcoma, as announced by the Company on March 21, 2024.

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April:

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Rare Pediatric Disease Designation (“RPDD”) to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET

Lisata Therapeutics, Inc. (LSTA) Q4 2023 Earnings Call Transcript

Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.J.

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for twelve months ended December 31, 2023, on Thursday, February 29, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City.

Lisata Therapeutics to Present at BIO CEO & Investor Conference

Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

BASKING RIDGE, NJ, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will deliver a company presentation at the upcoming Sequire Investor Summit being held January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

LSTA1, the Company's lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma LSTA1, the Company's lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

Lisata Therapeutics Inc, a clinical-stage pharmaceutical firm specializing in innovative cancer therapies, said it has completed patient enrollment in the Phase 2b ASCEND trial for its pancreatic cancer drug candidate, LSTA1, nearly six months ahead of schedule. The ASCEND trial, a critical initiative for Lisata, involves 155 patients and compares the standard-of-care (SoC) gemcitabine and nab-paclitaxel against SoC plus LSTA1.

Lisata Therapeutics accelerates pancreatic cancer trial, expects early data in 2024

BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.

Lisata Therapeutics to Present at NobleCon19 Investor Conference

Lisata Therapeutics, Inc. (LSTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy

Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants John Menditto - VP, IR and Corporate Communications Dr. David Mazzo - President and Chief Executive Officer Dr. Kristen Buck - EVP, Research and Development and Chief Medical Officer James Nisco - VP, Finance and Treasury Conference Call Participants Steve Brozak - WBB Securities Kemp Dolliver - Brookline Capital Markets Pete Enderlin - MAZ Partners Operator Welcome to the Lisata Therapeutics Third Quarter 2023 Financial Results and this is a day conference call. Currently, all participants are in a listen-only mode.

Lisata Therapeutics, Inc. (LSTA) Q3 2023 Earnings Call Transcript

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for third quarter ended September 30, 2023, on Thursday, November 2, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.

Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up

BASKING RIDGE, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the European Medicines Agency (“EMA”) Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the Company's lead product candidate for the treatment of pancreatic cancer.

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at two upcoming conferences in October. Details of the events are as follows:

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, or esophageal squamous cell carcinoma

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.

News for Lisata Therapeutics Inc Stock (LSTA)